Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Trial of IGF-1R Inhibitor Figitumumab Combined with Carbo/Taxol Officially Closed
Author
Howard (Jack) West, MD

The trial of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor figitumumab in combination with carbo/taxol as first line therapy for advanced NSCLC was officially closed after it was determined that the experimental arm would not have a meaningful chance of appearing superior to standard carbo/taxol with a placebo ("futility analysis"). Dr. Sanborn had previously written about this trial after it was put on hold due to safety concerns with this combination.

Importantly, this agent is still being studied in combination with Tarceva, and that trial is still ongoing, as are trials with this agent in other cancers. It's not clear whether the safety concerns figitumumab in combination with chemo are specific to this one agent or whether other agents that inhibit the new target IGF-1R as a potentially important anti-cancer treatment will also show show safety problems and lack of efficacy in combination with chemo, nor do we know whether the issues are specific to carbo/taxol or could be a problem with other chemotherapy combinations.

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora